GT Biopharma, Inc. (GTBP)
NASDAQ: GTBP · Real-Time Price · USD
0.4300
+0.0139 (3.34%)
At close: Jun 26, 2026, 4:00 PM EDT
0.4358
+0.0058 (1.35%)
After-hours: Jun 26, 2026, 7:53 PM EDT
GT Biopharma Employees
GT Biopharma had 1 employees as of December 31, 2025. The number of employees did not change compared to the previous year.
Employees
1
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$37,042,000
Market Cap
15.51M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 1 | 0 | - | 1 | 0 |
| Dec 31, 2024 | 1 | -1 | -50.00% | 1 | 0 |
| Dec 31, 2023 | 2 | 0 | - | 2 | 0 |
| Dec 31, 2022 | 2 | -6 | -75.00% | 2 | 0 |
| Dec 31, 2021 | 8 | 5 | 166.67% | 8 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Quince Therapeutics | 38 |
| Lunai Bioworks | 29 |
| Passage Bio | 24 |
| Citius Pharmaceuticals | 23 |
| Moleculin Biotech | 17 |
| Atossa Therapeutics | 16 |
| Cocrystal Pharma | 10 |
| Tempest Therapeutics | 5 |
GTBP News
- 10 days ago - GT Biopharma Proxy statement: Proxy filing - Filings
- 19 days ago - Three Cancer Drugs Have Reached the Clinic: Inside GT Biopharma's TriKE Bet - GlobeNewsWire
- 27 days ago - GT Biopharma Provides Update on Pipeline Discovery Activities from Newly Implemented AI-Based Technological Initiatives - GlobeNewsWire
- 6 weeks ago - GT Biopharma Reports First Quarter 2026 Financial Results - GlobeNewsWire
- 6 weeks ago - GT Biopharma Quarterly report: Q1 2026 - Filings
- 6 weeks ago - GT Biopharma Earnings release: Q1 2026 - Filings
- 6 weeks ago - GT Biopharma doses first patient in GTB-5550 trial - TheFly
- 6 weeks ago - GT Biopharma Announces First Patient Dosed in Phase 1 Trial of GTB-5550, a B7-H3-Targeted Natural Killer (NK) Cell Engager for Solid Tumors - GlobeNewsWire